Wilkins Investment Counsel Inc. Has $11.73 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Wilkins Investment Counsel Inc. increased its stake in IQVIA Holdings Inc. by 21.7% to hold 66,514 shares valued at approximately $11.73 million, making it the 25th largest holding in their portfolio.
• IQVIA Holdings reported a quarterly EPS of $2.81, exceeding expectations, alongside a 5.3% increase in year-over-year revenue, amounting to $4.02 billion.
• Institutional investors own a significant majority of 89.62% of IQVIA's stock, highlighting a strong institutional interest in the company.

Wilkins Investment Counsel Inc. lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 66,514 shares of the medical research company's stock after purchasing an additional 11,857 shares during the quarter. IQVIA accounts for 1.7% of Wilkins Investment Counsel Inc.'s holdings, making the stock its 25th biggest holding. Wilkins Investment Counsel Inc.'s holdings in IQVIA were worth $11,726,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Continuum Advisory LLC increased its holdings in IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after buying an additional 64 shares during the period. Ballentine Partners LLC boosted its position in shares of IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after acquiring an additional 69 shares in the last quarter. ST Germain D J Co. Inc. raised its position in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. Zions Bancorporation N.A. lifted its stake in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after purchasing an additional 85 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in shares of IQVIA by 10.7% in the 4th quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after purchasing an additional 90 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Up 3.5%

NYSE:IQV opened at $201.06 on Friday. The firm has a fifty day simple moving average of $155.96 and a two-hundred day simple moving average of $170.53. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The stock has a market capitalization of $34.18 billion, a price-to-earnings ratio of 29.10, a PEG ratio of 2.29 and a beta of 1.30. The company has a current ratio of 0.84, a quick ratio of 0.82 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the previous year, the company posted $2.64 earnings per share. The company's quarterly revenue was up 5.3% on a year-over-year basis. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. lowered their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Cowen reiterated a "buy" rating on shares of IQVIA in a research report on Wednesday. Citigroup reissued a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Robert W. Baird lifted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday. Finally, HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their target price for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Seven research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $226.95.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.